Government caps price of 6 formulations packs
New Delhi: Government has capped prices of six drug formulations packs, including pain killer Ibuprofen, anti-infective Metronidazole, among others.Drug firms such as Abbott Healthcare, Ipca Laboratories and Merck would be impacted by National Pharmaceutical Pricing Authority's (NPPA) move.The prices of six formulation packs have been fixed/ revised under Drug Price Control Order (DPCO),...
Login or Register to read the full article
New Delhi: Government has capped prices of six drug formulations packs, including pain killer Ibuprofen, anti-infective Metronidazole, among others.
Drug firms such as Abbott Healthcare, Ipca Laboratories and Merck would be impacted by National Pharmaceutical Pricing Authority's (NPPA) move.
The prices of six formulation packs have been fixed/ revised under Drug Price Control Order (DPCO), 2013, NPPA said in a statement.
Earlier this month, the NPPA had capped the prices of 18 formulation packs, including anti-diabetic Metformin HCl tablets, anti-bacterial Ceftriaxone Sodium injection packs and devices among others.
At present, the government caps prices of essential drugs based on the simple average of all medicines in a particular therapeutic segment with sales of more than 1 per cent.
In case of non-scheduled formulations companies are allowed to hike prices of medicines by only up to 10 per cent in a year.
The government had notified DPCO, 2013, which covers 680 formulations, effective May 15, 2014, replacing the 1995 order that regulated only 74 bulk drugs.
Drug firms such as Abbott Healthcare, Ipca Laboratories and Merck would be impacted by National Pharmaceutical Pricing Authority's (NPPA) move.
The prices of six formulation packs have been fixed/ revised under Drug Price Control Order (DPCO), 2013, NPPA said in a statement.
Earlier this month, the NPPA had capped the prices of 18 formulation packs, including anti-diabetic Metformin HCl tablets, anti-bacterial Ceftriaxone Sodium injection packs and devices among others.
At present, the government caps prices of essential drugs based on the simple average of all medicines in a particular therapeutic segment with sales of more than 1 per cent.
In case of non-scheduled formulations companies are allowed to hike prices of medicines by only up to 10 per cent in a year.
The government had notified DPCO, 2013, which covers 680 formulations, effective May 15, 2014, replacing the 1995 order that regulated only 74 bulk drugs.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd